Oncolytics Biotech Inc.
ONCY
$0.5796
-$0.0123-2.08%
NASDAQ
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Net Income | -12.33% | 15.35% | -3.70% | -13.70% | -8.29% |
Total Depreciation and Amortization | -0.54% | 8.71% | 9.57% | 7.58% | -0.93% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 126.75% | -348.98% | -679.21% | -860.15% | -492.68% |
Change in Net Operating Assets | 99.07% | 185.89% | 801.23% | 668.97% | 547.43% |
Cash from Operations | 6.71% | 11.42% | 1.01% | -10.62% | -17.24% |
Capital Expenditure | -2,869.49% | -5,670.00% | -1,411.11% | -96.22% | 86.34% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -- | -100.00% | 200.84% | 200.42% | 200.28% |
Cash from Investing | -101.17% | -540.46% | 197.66% | 199.88% | 199.95% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | 14.50% | 13.09% | 6.27% | -4.07% | -6.82% |
Issuance of Common Stock | -76.76% | -89.54% | 62.75% | 115.81% | 149.31% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | 173.14% | 117.71% | 114.19% | 100.00% |
Cash from Financing | -79.79% | -86.19% | 66.10% | 127.46% | 155.93% |
Foreign Exchange rate Adjustments | 403.98% | 154.61% | -43.74% | -96.22% | -125.26% |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -179.93% | -356.87% | 147.02% | 158.26% | 178.15% |